Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 4 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Endocrine 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Thyroid Neoplasms 3Wilms Tumor 2Thyroid Cancer, Papillary 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Carcinoma, Medullary 2Xanthogranuloma, Juvenile 1Thyroid Carcinoma, Anaplastic 1Neoplasms 1Lymphoma 1Histiocytic Sarcoma 1Gastrointestinal Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Sorafenib 10Magnetic Resonance Spectroscopy 10trametinib 8lenvatinib 8dabrafenib 7pembrolizumab 6Nivolumab 6Iodine-131 6Everolimus 6Sunitinib 5Paclitaxel 5vandetanib 4apatinib 4Thyrotropin Alfa 4Doxorubicin 4selpercatinib 3anlotinib 3Specimen Handling 3Radiotherapy 3Ipilimumab 3Iodine-124 3Fluorodeoxyglucose F18 3Cisplatin 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2tipifarnib 2surufatinib 2spartalizumab 2pazopanib 2omipalisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Neoplasms × selpercatinib × Clear all
NCT04759911 2026-05-20

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT04280081 2026-04-24

LIBRETTO-321

Eli Lilly and Company

Phase 2 Active not recruiting
77 enrolled 13 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms, Carcinoma, Medullary

NCT05668962 2024-12-12

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Massachusetts General Hospital

Phase 2 Recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡